Daugherty AL - Search Results

1

Evaluation of the Toxicity of Intravitreally Injected PLGA Microspheres and Rods in Monkeys and Rabbits: Effects of Depot Size on Inflammatory Response.

Thackaberry EA, Farman C, Zhong F, Lorget F, Staflin K, Cercillieux A, Miller PE, Schuetz C, Chang D, Famili A, Daugherty AL, Rajagopal K, Bantseev V. Thackaberry EA, et al. Among authors: daugherty al. Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4274-4285. doi: 10.1167/iovs.16-21334. Invest Ophthalmol Vis Sci. 2017. PMID: 28850638

2

Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response.

Cleland JL, Barrón L, Berman PW, Daugherty A, Gregory T, Lim A, Vennari J, Wrin T, Powell MF. Cleland JL, et al. J Pharm Sci. 1996 Dec;85(12):1346-9. doi: 10.1021/js960047b. J Pharm Sci. 1996. PMID: 8961151

3

Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response.

Cleland JL, Lim A, Daugherty A, Barron L, Desjardin N, Duenas ET, Eastman DJ, Vennari JC, Wrin T, Berman P, Murthy KK, Powell MF. Cleland JL, et al. J Pharm Sci. 1998 Dec;87(12):1489-95. doi: 10.1021/js980263f. J Pharm Sci. 1998. PMID: 10189254

4

Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes.

Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL. Lam XM, et al. Among authors: daugherty al. J Control Release. 2000 Jul 3;67(2-3):281-92. doi: 10.1016/s0168-3659(00)00224-8. J Control Release. 2000. PMID: 10825561

5

Development of poly-(D,L-lactide--coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis.

Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J, Cuthbertson A. Cleland JL, et al. J Control Release. 2001 May 14;72(1-3):13-24. doi: 10.1016/s0168-3659(01)00258-9. J Control Release. 2001. PMID: 11389981

6

In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies.

Bown HK, Bonn C, Yohe S, Yadav DB, Patapoff TW, Daugherty A, Mrsny RJ. Bown HK, et al. J Control Release. 2018 Mar 10;273:13-20. doi: 10.1016/j.jconrel.2018.01.015. Epub 2018 Feb 6. J Control Release. 2018. PMID: 29355621

7

Ocular drugs and drug delivery systems - Current trends and future perspectives.

Rupenthal ID, Daugherty AL. Rupenthal ID, et al. Among authors: daugherty al. Drug Discov Today. 2019 Aug;24(8):1425-1426. doi: 10.1016/j.drudis.2019.07.005. Epub 2019 Jul 19. Drug Discov Today. 2019. PMID: 31330186 No abstract available.

8

Sustained release formulations of rhVEGF₁₆₅ produce a durable response in a murine model of peripheral angiogenesis.

Daugherty AL, Rangell LK, Eckert R, Zavala-Solorio J, Peale F, Mrsny RJ. Daugherty AL, et al. Eur J Pharm Biopharm. 2011 Jun;78(2):289-97. doi: 10.1016/j.ejpb.2011.03.011. Epub 2011 Mar 21. Eur J Pharm Biopharm. 2011. PMID: 21426936

9

Formulation and delivery issues for monoclonal antibody therapeutics.

Daugherty AL, Mrsny RJ. Daugherty AL, et al. Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):686-706. doi: 10.1016/j.addr.2006.03.011. Epub 2006 May 22. Adv Drug Deliv Rev. 2006. PMID: 16839640 Review.

10

Magnetic resonance angiography reveals therapeutic enlargement of collateral vessels induced by VEGF in a murine model of peripheral arterial disease.

Greve JM, Chico TJ, Goldman H, Bunting S, Peale FV Jr, Daugherty A, van Bruggen N, Williams SP. Greve JM, et al. J Magn Reson Imaging. 2006 Nov;24(5):1124-32. doi: 10.1002/jmri.20731. J Magn Reson Imaging. 2006. PMID: 17029233

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters